Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
The Next Generation of Monoclonal Antibody Therapy
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, as a platform drug with potential in a variety of indications in solid-tumor oncology.
How it Works
The target of leronlimab (PRO 140) is the important immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of a variety of cells including white blood cells and cancer cells. Recent research has identified the CCR5 receptor as an important target for many disease processes including cancer metastasis and certain immunological conditions.
What Makes Leronlimab Different
Leronlimab is a humanized monoclonal antibody with a unique mechanism of action. Preclinical research has shown that leronlimab blocks calcium channel signaling of the CCR5 receptor when present on the cancer cell surface. It is believed that calcium channel signaling of the CCR5 receptor is a crucial component to the spread of metastatic cancer.
Email Alerts
Stay informed and receive company updates straight to your inbox.